```html

HSV‑2 Genital Herpes: A Complete Patient Guide

Overview

Herpes simplex virus type 2 (HSV‑2) is a DNA virus that primarily causes genital herpes. It is highly contagious and can be spread through sexual contact, including vaginal, anal, and oral sex. While HSV‑1 (commonly associated with cold sores) can also cause genital infections, HSV‑2 accounts for roughly 70‑80 % of genital herpes cases worldwide.

**Who it affects** – Anyone who is sexually active can acquire HSV‑2, regardless of gender, age, or sexual orientation. In the United States, an estimated ≈ 12 % of people aged 14‑49 are infected (about 1 in 8). Prevalence is higher in women (≈ 15 %) than men (≈ 10 %) because of the larger mucosal surface area of the female genital tract. Globally, the World Health Organization estimates that more than 400 million adults live with HSV‑2.

**Key points**

• HSV‑2 is lifelong; once infected, the virus remains dormant in nerve cells.
• Most people are unaware they have HSV‑2 because initial infections can be mild or asymptomatic.
• Recurring outbreaks are generally less severe than the primary episode.

Symptoms

Symptoms can appear 2‑12 days after exposure, but many infections are silent. When symptoms do occur, they fall into three categories: prodrome, lesions, and systemic signs.

Prodrome (early warning)

• Itching, tingling, or burning in the genital or anal area.
• Localized pain or discomfort that may precede visible sores by several hours to a day.

Skin‑level lesions

• Small red bumps that quickly become fluid‑filled blisters.
• Blisters may burst, leaving tender ulcers that eventually crust over.
• Typical lesion distribution: vulva, cervix, vagina, penis, scrotum, perianal skin, or inner thighs.
• Lesions usually heal within 2‑4 weeks for the first outbreak and 7‑10 days for recurrences.

Systemic symptoms (more common in primary infection)

• Fever, chills, and malaise.
• Headache, muscle aches, and swollen lymph nodes (especially inguinal nodes).
• Urethral discharge or painful urination (dysuria) if lesions involve the urethra.

Asymptomatic shedding

Even without visible lesions, the virus can be present on the skin and be transmitted. Asymptomatic shedding occurs on ~10‑20 % of days in people with recurrent genital HSV‑2.

Causes and Risk Factors

HSV‑2 is transmitted through direct contact with infected skin or mucous membranes. The virus enters through micro‑abrasions, even if the skin looks normal.

Primary causes

• Unprotected vaginal, anal, or oral sex with an infected partner.
• Skin‑to‑skin contact during genital touching or sexual activity.
• Contact with infected secretions (e.g., semen, vaginal fluid) that contain the virus.

Risk factors that increase susceptibility

• Younger age – highest incidence in people aged 15‑34.
• Multiple sexual partners or a partner with a known HSV infection.
• Other sexually transmitted infections (STIs), especially HIV, which can increase viral shedding.
• History of genital trauma (e.g., from childbirth, surgery, or vigorous sexual activity).
• Use of immunosuppressive medications (e.g., corticosteroids, biologics) or conditions such as HIV/AIDS.
• Engaging in sexual activity while the partner has an active outbreak.

Diagnosis

Because many infections are silent, testing is often prompted by symptoms, partner notification, or routine STI screening.

Clinical examination

Healthcare providers will visually inspect the genital area for characteristic vesicles or ulcers and ask about prodromal sensations.

Laboratory tests

• Polymerase Chain Reaction (PCR) swab – the most sensitive test; a sample from a lesion is amplified to detect viral DNA.
• Viral culture – isolates live virus from a lesion; less sensitive than PCR and less often used.
• Type‑specific serology (IgG) – detects antibodies to HSV‑1 and HSV‑2 in blood. Useful when lesions are absent.
• Rapid point‑of‑care tests – emerging immunoassays give results within 30 minutes but are less accurate than PCR.

Guidelines from the CDC recommend testing both the lesion (if present) and a blood sample for type‑specific antibodies to differentiate HSV‑1 from HSV‑2.

Treatment Options

While there is no cure, antiviral therapy can dramatically reduce symptoms, shorten outbreaks, and lower transmission risk.

First‑line antiviral medications

Medication	Typical Dose	Duration (primary infection)
Acyclovir (Zovirax)	400 mg orally 5×/day	7‑10 days
Valacyclovir (Valtrex)	1 g orally 3×/day	7‑10 days
Famciclovir (Famvir)	250 mg orally 3×/day	7‑10 days

For recurrent outbreaks, a “episodic” regimen (same drugs, shorter course of 3‑5 days) is usually sufficient.

Suppressive (daily) therapy

• Valacyclovir 500 mg once daily or Acyclovir 400 mg twice daily reduces outbreak frequency by ~70 % and cuts asymptomatic shedding by ~50 %.
• Suppressive therapy is recommended for:
  • People with ≥4 outbreaks per year.
  • Those who are pregnant or planning pregnancy.
  • Individuals seeking to minimize transmission to an uninfected partner.

Adjunctive measures

• Pain control – acetaminophen or ibuprofen for fever and discomfort.
• Topical anesthetics (lidocaine 5 % gel) for localized relief.
• Warm baths or sitz baths can soothe lesions.
• Good genital hygiene – gentle washing with mild soap, pat dry.

Procedural options

Procedures are rarely needed but may be considered for atypical lesions that mimic HSV (e.g., biopsies to rule out malignancy) or for chronic ulcerations that fail to heal.

Living with HSV‑2 Genital Herpes

Managing HSV‑2 is as much about lifestyle as medication. Below are practical tips for day‑to‑day living.

Self‑care during an outbreak

• Start antiviral therapy as soon as prodromal symptoms appear – this often aborts the outbreak.
• Wear loose, breathable cotton underwear to reduce friction.
• Avoid sexual activity while lesions are present; use condoms afterwards as shedding can still occur.
• Keep the area clean and avoid shaving or waxing the genital area until lesions have healed.

Emotional and psychosocial well‑being

• Know that HSV‑2 is common; stigma often exceeds the medical impact.
• Consider counseling or support groups (e.g., HSV Support Community, local STI clinics).
• Open communication with partners builds trust and facilitates shared decision‑making about prevention.

Pregnancy considerations

• Women with HSV‑2 should inform their obstetrician early.
• Suppressive therapy (valacyclovir 500 mg daily) from 36 weeks gestation reduces the risk of neonatal herpes.
• If active lesions appear at labor, a Cesarean delivery is recommended to protect the newborn.

Regular medical follow‑up

• Annual STI screening, especially if you have new or multiple partners.
• Review medication side‑effects (e.g., renal function for chronic acyclovir).
• Discuss vaccine research updates – several therapeutic HSV vaccines are in phase III trials (2024).

Prevention

Preventing HSV‑2 acquisition or transmission involves a combination of behavioral and biomedical strategies.

• Consistent condom use – reduces risk by ~30‑50 % but does not eliminate it because virus can be shed from uncovered skin.
• Dental dams for oral‑genital contact.
• Abstain from sex during an outbreak or prodrome.
• Suppressive antiviral therapy for infected individuals who have frequent outbreaks or an uninfected partner.
• Partner testing and disclosure – knowing each other’s status informs safer‑sex decisions.
• Vaccination – a prophylactic HSV vaccine is not yet available, but research is ongoing (CDC, 2024). Stay informed about clinical trial participation if eligible.

Complications

Although many people experience mild disease, untreated HSV‑2 can lead to serious health issues.

Genital complications

• Recurrent painful ulcers can cause urinary retention or dysuria.
• Secondary bacterial infection of lesions (cellulitis) requiring antibiotics.

Neonatal herpes

The most severe consequence of maternal HSV‑2 is neonatal infection, which can be disseminated, causing encephalitis, skin/eye/mouth disease, or death. Prompt antiviral therapy (acyclovir) and delivery planning reduce this risk dramatically.

Psychological impact

Depression, anxiety, and sexual dysfunction are common. Early counseling can mitigate long‑term emotional sequelae.

Association with HIV

HSV‑2 ulcerations create mucosal breaches that facilitate HIV acquisition. Studies show a 2‑3‑fold increased risk of HIV seroconversion in HSV‑2–positive individuals (WHO, 2022).

When to Seek Emergency Care

Key Take‑aways

• HSV‑2 is a common, lifelong infection; most people acquire it in young adulthood.
• Early antiviral therapy shortens outbreaks and reduces transmission.
• Regular communication with health providers and sexual partners is essential for safe management.
• Complications are rare but can be severe, especially in newborns and immunocompromised individuals.
• Consistent condom use, suppressive therapy, and avoidance of sex during outbreaks are the cornerstone prevention strategies.

```